SPIA
NRXP icon

Steward Partners Investment Advisory’s NRX Pharmaceuticals NRXP Stock Holding History

Steward Partners Investment Advisory’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2 Hold
1
– – ﹤0.01% 4413
2025
Q4 		$3 Buy
+1
New +$3 ﹤0.01% 4300

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Steward Partners Investment Advisory's NRXP Position: Q1 2026 in Review

Steward Partners Investment Advisory held its NRX Pharmaceuticals (NRXP) position steady in Q1 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #4413.

Steward Partners Investment Advisory first reported a position in NRXP in Q4 2025 and has held it in 2 quarters since. The position peaked at $3 in Q4 2025. 33 funds tracked by Wall St. Rank hold NRXP as of Q1 2026.

  • Steward Partners Investment Advisory held 1 share of NRX Pharmaceuticals worth $2 as of Q1 2026.
  • Steward Partners Investment Advisory left its NRX Pharmaceuticals share count unchanged in Q1 2026.
  • NRX Pharmaceuticals made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #4413 holding.
  • Steward Partners Investment Advisory first reported a position in NRX Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Steward Partners Investment Advisory's NRX Pharmaceuticals position peaked at $3 in Q4 2025.
  • 33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.